- Ticker
- ACRS
- Price
- 16.90
- Stock movement up
- +0.05 (0.30%)
- Company name
- Aclaris Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Diagnostics & Research
- Markedsverdi
- 1.13B
- Ent verdi
- 1.11B
- Pris/omsetning
- 47.96
- Pris/bok
- 5.13
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- 62.97%
- 3 års avkastning
- 133.94%
- 5 års avkastning
- -6.47%
- 10 års avkastning
- -
Sist oppdatert: 2023-01-31
UTBYTTE
ACRS betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 47.96 |
| Pris til bok | 5.13 |
| EV i forhold til salg | 47.37 |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 66.68M |
| EPS (TTM) | -1.23 |
| FCF per aksje (TTM) | -0.99 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 23.50M |
| Bruttofortjeneste (TTM) | 11.90M |
| Driftsinntekter (TTM) | -83.67M |
| Netto inntekt (TTM) | -82.08M |
| EPS (TTM) | -1.23 |
| EPS (1 år fremover) | -1.69 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 50.66% |
| Driftsmargin (TTM) | -356.03% |
| Fortjenestemargin (TTM) | -349.26% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 61.65M |
| Netto fordringer | 597.00K |
| Samlede omløpsmidler | 256.57M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 6.99M |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 267.63M |
| Leverandørgjeld | 7.67M |
| Kortsiktig/nåværende langsiktig gjeld | 766.00K |
| Sum kortsiktig gjeld | 19.79M |
| Sum gjeld | 47.79M |
| Aksjonærenes egenkapital | 219.84M |
| Netto varige driftsmidler | 212.85M |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -65.53M |
| Kapitalutgifter (TTM) | 752.00K |
| Fri kontantstrøm (TTM) | -66.28M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -37.34% |
| Avkastning på eiendeler | -30.67% |
| Avkastning på investert kapital | -37.21% |
| Kontantavkastning på investert kapital | -30.04% |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 16.88 |
| Daglig høy | 17.50 |
| Daglig lav | 16.73 |
| Daglig volum | 452K |
| Tidenes høyeste | 32.99 |
| 1 år analytikerestimat | 32.50 |
| Beta | 0.58 |
| EPS (TTM) | -1.23 |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | 22 Feb 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACRS | S&P500 | |
| Nåværende prisfall fra toppnotering | -48.77% | -14.91% |
| Høyeste prisfall | -97.73% | -56.47% |
| Dato for høyeste fall | 18 Mar 2020 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -52.04% | -11.49% |
| Gj.snittlig tid til ny topp | 77 days | 13 days |
| Maks tid til ny topp | 1459 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
1.13B
Markedsverdi kategori
Small-cap
Beskrivelse
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Ansatte
72
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Neal S. Walker
Land
USA
By
Malvern
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
6. januar 2023
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for ...
29. november 2022
This week's Lab Notes has updates from bioMerieux, Avisti Technologies, Aclaris Therapeutics and more.
26. november 2022
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walke...
22. november 2022
Aclaris Therapeutics is a biotech play that is focused on "leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people ...
16. november 2022
WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
10. november 2022
Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
8. november 2022
- Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023 - Announced Patent License Agreement with Lilly for the Treatment ...
8. november 2022
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
26. oktober 2022
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
27. september 2022
Neste side